-$0.48 EPS Expected for Assembly Biosciences, Inc. (NASDAQ:ASMB) This Quarter

Wall Street analysts predict that Assembly Biosciences, Inc. (NASDAQ:ASMBGet Rating) will report earnings of ($0.48) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Assembly Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.57) and the highest estimate coming in at ($0.34). Assembly Biosciences posted earnings per share of ($0.55) in the same quarter last year, which would indicate a positive year over year growth rate of 12.7%. The firm is scheduled to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Assembly Biosciences will report full year earnings of ($2.00) per share for the current year, with EPS estimates ranging from ($2.31) to ($1.42). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.61) per share, with EPS estimates ranging from ($1.76) to ($1.49). Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMBGet Rating) last posted its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.48) EPS for the quarter, hitting analysts’ consensus estimates of ($0.48).

A number of equities analysts have commented on the company. StockNews.com assumed coverage on Assembly Biosciences in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. Truist Financial reduced their price objective on Assembly Biosciences from $15.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, April 1st. Finally, Mizuho initiated coverage on Assembly Biosciences in a research report on Tuesday, March 22nd. They set a “buy” rating and a $14.00 target price for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $7.02.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its holdings in Assembly Biosciences by 15,633.0% in the first quarter. JPMorgan Chase & Co. now owns 14,789 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 14,695 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of Assembly Biosciences in the fourth quarter worth about $31,000. Royal Bank of Canada increased its holdings in shares of Assembly Biosciences by 185.4% in the second quarter. Royal Bank of Canada now owns 10,319 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 6,703 shares in the last quarter. Cubist Systematic Strategies LLC increased its holdings in shares of Assembly Biosciences by 89.1% in the fourth quarter. Cubist Systematic Strategies LLC now owns 35,654 shares of the biopharmaceutical company’s stock worth $83,000 after acquiring an additional 16,800 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Assembly Biosciences in the fourth quarter worth about $83,000. Institutional investors and hedge funds own 52.63% of the company’s stock.

Assembly Biosciences stock opened at $1.54 on Friday. The firm has a market cap of $74.10 million, a P/E ratio of -0.51 and a beta of 0.88. The business’s fifty day moving average is $1.88 and its two-hundred day moving average is $2.05. Assembly Biosciences has a 52 week low of $1.32 and a 52 week high of $4.69.

About Assembly Biosciences (Get Rating)

Assembly Biosciences, Inc, a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.

Further Reading

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.